Skip to main content
HairCited

ミノキシジル 円形脱毛症

A

合計21,842名の参加者を対象とした48件の研究(メタアナリシス2件、RCT 1件を含む)に基づく。48件中37件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dalopecia\u002Dareata'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Minoxidil has strong evidence supporting its use for alopecia areata, with the majority of studies showing positive effects, and is widely used as both a topical and oral option for this condition.

  • 37 out of 48 studies show positive effects across a large pool of 21,842 participants
  • Available in topical (2% and 5%) and oral low-dose formulations
  • Extends the hair growth phase and increases blood supply to hair follicles
  • Often used in combination with other treatments like corticosteroids for enhanced effectiveness

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Case Reports n=1
Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case …
Dose: None vs: None Outcome: hair regrowth in severe alopecia areata 効果: None None

対象集団: patient with severe alopecia areata with suboptimal response to tofacitinib

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo 効果: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs: Placebo 効果: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None
retrospective cohort study n=321
Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Dose: Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi vs: Placebo 効果: 91.3% received definitive remote diagnosis; only 8.7% required in-person follow-up. AA most common ( None

Key Statistics

122

研究数

27416

参加者数

Positive

A

グレード

Referenced Papers

Dermatologic clinics 2025 5 件の引用
Pediatric dermatology 2025 5 件の引用
Journal of the … 2025 2 件の引用
International journal of … 2025 1 件の引用
Journal of clinical … 2025 1 件の引用
Archives of dermatological … 2025
International journal of … 2024 39 件の引用
American family physician 2024 8 件の引用
Skin health and … 2024 7 件の引用
Journal of the … 2024 7 件の引用
The Journal of … 2024 2 件の引用
Archives of dermatological … 2023 16 件の引用
The Cochrane database … 2023 2 件の引用
The Journal of … 2022 170 件の引用
Journal of the … 2022 90 件の引用
Dermatology and therapy 2022 43 件の引用
Skin appendage disorders 2022 7 件の引用
JAAD case reports 2022 2 件の引用
The American Journal … 2022 2 件の引用
Clinical reviews in … 2021 304 件の引用
Journal of dermatological … 2021 51 件の引用
Dermatologic therapy 2021 30 件の引用
American journal of … 2020 127 件の引用
International journal of … 2020 58 件の引用
Recent patents on … 2020 5 件の引用
The journal of … 2020 3 件の引用
The Australasian journal … 2019 152 件の引用
American journal of … 2019 84 件の引用
Journal of the … 2019 50 件の引用
Expert opinion on … 2019 34 件の引用
Klinicka onkologie : … 2019 11 件の引用
Journal of the … 2018 114 件の引用
Dermatology online journal 2018
American family physician 2017 141 件の引用
Lasers in medical … 2017 43 件の引用
American journal of … 2017 32 件の引用
Actas dermo-sifiliograficas 2017 17 件の引用
Deutsches Arzteblatt international 2016 99 件の引用
Skinmed 2016 2 件の引用
Current problems in … 2015 322 件の引用
The Medical clinics … 2015 66 件の引用
Canadian family physician … 2015 31 件の引用
Seminars in cutaneous … 2015 27 件の引用
The journal of … 2015 25 件の引用
Current problems in … 2015 18 件の引用
Der Internist 2015
Lasers in surgery … 2014 243 件の引用
American journal of … 2014 82 件の引用
Expert opinion on … 2014 57 件の引用
Giornale italiano di … 2014 18 件の引用
Giornale italiano di … 2014
International journal of … 2013 61 件の引用
Recent patents on … 2011 6 件の引用
Seminars in cutaneous … 2009 85 件の引用
American family physician 2009
The Cochrane database … 2008 222 件の引用
Current opinion in … 2008 31 件の引用
International journal of … 2007 185 件の引用
Alopecia areata. Case Report
Dermatology nursing 2007
The Australasian journal … 2006
Journal of the … 2005 44 件の引用
Cleveland Clinic journal … 2005
Praxis 2003 28 件の引用
American family physician 2003 2 件の引用
American family physician 2003
American journal of … 2000 28 件の引用
International journal of … 1999 16 件の引用
Dermatologic clinics 1998 121 件の引用
American family physician 1990
Dermatologic clinics 1987
Journal of the … 1984 122 件の引用
Journal of the … 1984
Archives of dermatology 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

topical:
2-5% solution, twice daily

上限量: 5% topical solution

研究で検討された用量

用量 期間 効果 N
None -- Neutral --
None -- Positive 1
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Mixed --
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri -- Positive --
Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi -- Positive 321
None -- Mixed --
None -- Mixed 1

推奨摂取タイミング: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

報告されている副作用

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

既知の相互作用

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

耐容上限摂取量: 5% topical solution

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does ミノキシジル help with 円形脱毛症?
Based on 122 studies with 27,416 participants, there is strong evidence from multiple clinical trials that ミノキシジル may support 円形脱毛症 management. Our evidence grade is A (Strong Evidence).
How much ミノキシジル should I take for 円形脱毛症?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of ミノキシジル?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for ミノキシジル and 円形脱毛症?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 122 peer-reviewed studies with 27,416 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。